Meek, Benson
Desai, Nuti
Moore, Donald C.
Tran, Thuy
Knovich, Mary Ann
Arnall, Justin http://orcid.org/0000-0003-0901-4866
Article History
Received: 4 November 2022
Accepted: 9 November 2022
First Online: 28 November 2022
Declarations
:
: N/A. This is a case report of therapy selection and response to therapy outside of a clinical trial. This article does not contain any studies with human participants performed by any of the authors.
: N/A. Institutional review board reviewed, and patient consent identified as not required.
: Donald Moore has served on advisor boards for Pfizer, AstraZeneca, and Janssen. Justin Arnall is supported by Novo Nordisk (Hemophilia) Speaker’s Bureau, CTI Biopharma Advisory Board. The rest of the authors declare no competing interests.